|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2014 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 10/20/2014 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
EPA Regulations on Agricultural Biotechnology
Efficient Science-Based Review of Biotech Products
Genetically Engineered (GE) Animals
FDA Approval
H.R. 4800/S. 2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
H.R. 4432: Safe and Accurate Food Labeling Act
Funding for the USDA
H.R. 4800/S. 2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Foreign Agricultural Biotechnology Laws and Regulations
Asynchrony of International Approvals
China Biotechnology Regulations
Like-minded Countries Initiatives
Funding for Biomass Crop Assistance Program
H.R. 4800/S. 2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Transatlantic Trade and Investment Partnership
Ag-Biotech Issues
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Review of Biotech Products
USDA Decision on GE Crops Environmental Impact Statement
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
Joseph |
Damond |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
Del Monte |
|
|
|
Anna |
Weinstein |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
FDA Approval
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Anna |
Weinstein |
|
|
|
Brent |
Del Monte |
|
|
|
Cathleen |
Enright |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for the USDA
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for FDA
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for National Institutes of Health
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for Biomass Crop Assistance Program
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Sequestration of PDUFA Fees
S. 1413: FDA User Fee Protection Act
Funding for Renewable Chemicals/Bio-based Products
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Funding for Biofuels
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Biorefineries
Implementation of the Agricultural Act of 2014
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), Office of Management & Budget (OMB), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Phyllis |
Arthur |
|
|
|
Rina |
Singh |
|
|
|
Tom |
DiLenge |
|
|
|
Catharine |
Harris |
|
|
|
Brent |
Del Monte |
|
|
|
Derrick |
White |
|
|
|
Kelly |
Cappio |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patenting of Humanitarian Technologies
S. 712: Patents for Humanity Program Improvement Act of 2013
Patent Reform
H.R. 3309: Innovation Act of 2013
S. 1013: Patent Abuse Reduction Act of 2013
S. 1720: Patent Transparency and Improvements Act of 2013
S. 866: Patent Quality Improvement Act of 2013
Targeting Rogue and Opaque Letters (TROL) Act of 2014 (Discussion Draft)
FTC Regulation of Patent Demand Letters (Senate Commerce Committee Discussion Draft)
Intellectual Property International Enforcement
Compulsory Licensing
India Issues
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
Intellectual Property Issues
Patenting of Biological Inventions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derrick |
White |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Joseph |
Damond |
|
|
|
Charles |
Fritts |
|
|
|
Anna |
Weinstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Sunshine Act Implementation
21st Century Cures Initiative
Genetically Engineered (GE) Animals
FDA Approval
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
H.R. 4432: Safe and Accurate Food Labeling Act
Funding for FDA
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Drug Evaluation and Review
Compassionate Use/Expanded Access
Implementation of the FDA Safety and Innovation Act
Special Medical Use/Limited Population Drug
Biosimilars
Colombia Biologics Regulations
Implementation of Affordable Care Act
Interchangeability and Pharmacy Substitution
Naming
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Review of Biotech Products
USDA Decision on GE Crops Environmental Impact Statement
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
Cartier |
Esham |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Derrick |
White |
|
|
|
Dana |
O'Brien |
|
|
|
Catharine |
Harris |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
|
Matthew |
O'Mara |
|
|
|
Kelly |
Cappio |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeffrey |
Peters |
|
|
|
Laurel |
Todd |
|
|
|
Phyllis |
Arthur |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Funding for Biofuels
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Biofuels (Non-Funding)
Accelerated Depreciation Extension
Climate Change Benefits
Production Tax Credit Extension
Renewable Fuel Standard
H.R. 3758: Second Generation Biofuel Extension Act of 2013
S. 2260: EXPIRE Act of 2014
Renewable Chemicals/Bio-based Products (Non-Funding)
Implementation of the Agriculture Act of 2014
Bonus Depreciation for Renewable Chemical Facilities
S. 2260: EXPIRE Act of 2014
Funding for Biomass Crop Assistance Program
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Renewable Chemicals/Bio-based Products
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Funding for Biorefineries
Implementation of the Agricultural Act of 2014
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Brent |
Del Monte |
|
|
|
Erick |
Lutt |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Review and Labeling of Food Derived From Biotechnology
H.R. 4432: Safe and Accurate Food Labeling Act
Genetically Engineered (GE) Animals
FDA Approval
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
Anna |
Weinstein |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Funding for Biofuels
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Biofuels (Non-Funding)
Accelerated Depreciation Extension
Climate Change Benefits
Production Tax Credit Extension
Renewable Fuel Standard
H.R. 3758: Second Generation Biofuel Extension Act of 2013
S. 2260: EXPIRE Act of 2014
Renewable Chemicals/Bio-based Products (Non-Funding)
Implementation of the Agriculture Act of 2014
Bonus Depreciation for Renewable Chemical Facilities
S. 2260: EXPIRE Act of 2014
Funding for Biomass Crop Assistance Program
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Renewable Chemicals/Bio-based Products
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
Funding for Biorefineries
Implementation of the Agricultural Act of 2014
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
H.R.4923: Energy and Water Development and Related Agencies Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA), Office of Management & Budget (OMB), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Brent |
Del Monte |
|
|
|
Erick |
Lutt |
|
|
|
Tom |
DiLenge. |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Funding for National Institutes of Health
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Biosimilars
Naming
Colombia Biologics Regulations
Implementation of Affordable Care Act
Interchangeability and Pharmacy Substitution
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Vaccine Access/Financing
Implementation of Affordable Care Act
S.2694: Ensuring Access to Primary Care for Women and Children Act
340B Drug Pricing Program
Implementation of Affordable Care Act
Program Implementation & Oversight
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for FDA
H.R. 4800/S.2389: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Reimbursement for Innovative Products
Medicare Part B Physician-Administered Products
Medicare Part D Prescription Drug Program
CMS Proposed Rule on Protected Classes
Sequestration of PDUFA Fees
S. 1413: FDA User Fee Protection Act
Drug Evaluation and Review
Compassionate Use/Expanded Access
Special Medical Use/Limited Population Drug
Implementation of the FDA Safety and Innovation Act
Orphan Drug Act Tax Credit
Clinical Trial Data Sharing and Disclosure
EU Policies
Canadian Policies
Sunshine Act Implementation
Affordable Care Act Implementation
Third Party Support of Patient Premiums and Cost-Sharing Obligations
21st Century Cures Initiative
TransPacific Partnership
Regulatory Transparency
Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
Regulatory Harmonization
Reimbursement Transparency
Intellectual Property Issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Natl Security Council (NSC), Office of Management & Budget (OMB), U.S. Trade Representative (USTR), Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catharine |
Harris |
|
|
|
Andrew |
Emmett |
|
|
|
Charles |
Fritts |
|
|
|
Joseph |
Damond |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Kelly |
Cappio |
|
|
|
Brent |
DelMonte |
|
|
|
Cartier |
Esham |
|
|
|
Jeffrey |
Peters |
|
|
|
Charles |
Crain |
|
|
|
Shelley |
Mui-Lipnik |
|
|
|
Hans |
Sauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), Office of Management & Budget (OMB),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derrick |
White |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Kelly |
Cappio |
|
|
|
Brent |
DelMonte |
|
|
|
Anna |
Weinstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015
21st Century Cures Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Management & Budget (OMB), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sara |
Radcliffe |
|
|
|
Cartier |
Esham |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
DelMonte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Derrick |
White |
|
|
|
Jeffrey |
Peters |
|
|
|
Laurel |
Todd |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
21st Century Cures Initiative
Reimbursement for Innovative Products
Medicare Part B Physician-Administered Products
Medicare Part D Prescription Drug Program: CMS Proposed Rule on Protected Classes
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brent |
DelMonte |
|
|
|
Laurel |
Todd |
|
|
|
Jeffrey |
Peters |
|
|
|
Jeanne |
Haggerty |
|
|
|
Catharine |
Harris |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Sara |
Radcliffe |
|
|
|
Tom |
DiLenge |
|
|
|
Phyllis |
Arthur |
|
|
|
Cartier |
Esham |
|
|
|
Kelly |
Cappio |
|
|
|
. |
. |
|
|
|
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Sarbanes Oxley Section 404 (b)
Mandatory Audit Firm Rotation
H.R. 1564/S. 1526: The Audit Integrity and Job Protection Act
Capital Formation Investment Incentives
Reform of Capital Gains Rules
Reform of Net Operating Loss Rules
Reform of Passive Loss Rules
S. 1658: The Start-up Jobs and Innovation Act
H.R. 4855: The PARTNER Act
S.2715: The COMPETE Act
Expansion of Exemption under SEC Regulation A
H.R. 4565: Startup Capital Modernization Act
Proposed SEC Rule on Reg A+
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
H.R. 2629: The Fostering Innovation Act
XBRL Exemption for Small Public Companies
H.R. 4164: Small Company Disclosure Simplification Act
H.R. 5405: The Promoting Job Creation and Reducing Small Business Burdens Act
Stock Exchange Tick Size
H.R. 3448: The Small Cap Liquidity Reform Act
H.R. 1952: The Spread Pricing Liquidity Act
Capital Market Enhancements
H.R. 3623: Improving Access to Capital for Emerging Growth Companies Act
H.R. 4568: Small Business Freedom to Grow Act
H.R. 4569: Disclosure Modernization and Simplification Act
H.R. 4571: To direct the SEC to revise its rules so as to increase the threshold amount for requiring issuers to
provide certain disclosures relating to compensatory benefits plans
H.R. 4697: To require the SEC to revise the definition of a WKSI to reduce the worldwide market value threshold
under the definition
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Brent |
DelMonte |
|
|
|
Cartier |
Esham |
|
|
|
Derrick |
White |
|
|
|
Tom |
DiLenge |
|
|
|
Anna |
Weinstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Bonus Depreciation
S. 2260: EXPIRE Act of 2014
Tax Reform
Orphan Drug Act Tax Credit
Renewable Chemicals/Bio-based Products
Bonus Depreciation for Renewable Chemical Facilities
S. 2260: EXPIRE Act of 2014
Biofuels
Accelerated Depreciation Extension
Production Tax Credit Extension
H.R. 3758: Second Generation Biofuel Extension Act of 2013
S. 2260: EXPIRE Act of 2014
Research & Development Tax Credit Reforms
Extension
Permanency
H.R. 4438: American Research & Competitiveness Act of 2014
S. 2260: EXPIRE Act of 2014
S. 2715: The COMPETE Act
S.193: The Start-up Innovation Credit Act
Capital Formation Investment Incentives
Reform of Capital Gains Rules
Reform of Net Operating Loss Rules
Reform of Passive Loss Rules
H.R. 4855: The PARTNER Act
S. 1658: The Start-up Jobs and Innovation Act
S. 2715: The COMPETE Act
Controlled Foreign Corporation Look-Through Rule Extension
S. 2260: EXPIRE Act of 2014
Inversions
H.R.4870: Department of Defense Appropriations Act for FY 2015
H.R.5016: Financial Services and General Government Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Erick |
Lutt |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Derrick |
White |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Charles |
Crain |
|
|
|
Brent |
Del Monte |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Cartier |
Esham |
|
|
|
Anna |
Weinstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Intellectual Property International Enforcement
Compulsory Licensing
India
Foreign Agricultural Biotechnology Laws and Regulations
Asynchrony of International Approvals
China Biotechnology Regulations
Like-minded Countries Initiatives
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
Regulatory Transparency
Transatlantic Trade and Investment Partnership
Ag-Biotech Issues
Intellectual Property Issues
Regulatory Harmonization
Reimbursement Transparency
Biosimilars
Colombia Biologics Regulations
Clinical Trial Data Sharing and Disclosure
EU Policies
Canadian Policies
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Jeffrey |
Peters |
|
|
|
Brent |
DelMonte |
|
|
|
Joseph |
Damond |
|
|
|
Jeanne |
Haggerty |
|
|
|
Charles |
Fritts |
|
|
|
Matthew |
O'Mara |
|
|
|
Dana |
O'Brien |
|
|
|
Derrick |
White |
|
|
|
Hans |
Sauer |
|
|
|
Cathleen |
Enright |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |